Phaseline

Targets › LONP1

LONP1 (Lon protease homolog, mitochondrial): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Metabolic and endocrine; next expected readout Oct 2027.

ATP-dependent serine protease that mediates the selective degradation of misfolded, unassembled or oxidatively damaged polypeptides as well as certain short-lived regulatory proteins in the mitochondrial matrix. Endogenous substrates include mitochondrial steroidogenic acute regulatory (StAR) protein, DELE1, helicase Twinkle (TWNK) and the large ribosomal subunit protein MRPL32/bL32m. (UniProt, P36776)

Open in Phaseline: the race on LONP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pharming TechnologiesKL1333 (napazimone)
LONP1 activator
LONP1Phase 2Primary Mitochondrial Disease; Mitochondrial DiseasesOct 2027

Conditions

Primary Mitochondrial Disease (1) Mitochondrial Diseases (1)

Modalities

small molecule (1)

Companies

Pharming Technologies (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.